Disrupting your body clock could increase your cancer risk

Researchers from the Charit é-Medical University in Berlin believe people's internal body clocks likely act as tumour suppressors. Someone is diagnosed with cancer every two minutes in the UK.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

ConclusionsThe onset of a second primary tumour was related with the primary treatment given; thus the risk for those treated with radiotherapy and androgen deprivation therapy more than doubled.ResumenIntroducción y objetivosLa aparición de segundos tumores primarios en pacientes con cáncer de próstata de alto riesgo debe tenerse en cuenta en la evolución natural de la enfermedad. Nuestro objetivo es evaluar la influencia del tratamiento primario con intención curativa de dichos pacientes en el desarrollo de segundos tumores primarios.Material y métodosEstudio retrospectivo...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Publication date: Available online 13 December 2018Source: Actas Urológicas Españolas (English Edition)Author(s): J.M. Cózar, B. Miñana, F. Gómez-Veiga, A. Rodríguez-Antolín, GESCAP GroupAbstractAimsTo describe the 3-year progression-free survival (PFS), overall survival (OS) and disease-specific mortality in the prospective prostate cancer GESCAP cohort, as well as the progression to castration resistance in patients on hormone therapy.Material and methodsProspective, observational, epidemiological, multicentre study. Of the 4087 patients recruited, 3843 were evaluable. The...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
ConclusionsThe diagnostic performance of CB in patients with at least one previous negative biopsy was 44%, increasing according to the PI-RADS grade, and low in PI-RADS 3. No clinical variable predictive of cancer was found in patients with PI-RADS 3.ResumenIntroducciónEvaluación de la efectividad de la biopsia cognitiva (BC) en los pacientes con sospecha clínica de cáncer de próstata (caP) y al menos una biopsia negativa (BTR).Material y métodoAnálisis retrospectivo de 144 pacientes con al menos una BTR y una resonancia magnética nuclear (RMN) previa. Los nód...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
ConclusionsPatient portals may offer an opportunity to build sustainable programs for decision support and assistance that are integrated with clinic workflows and processes.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Claire Daly, 34, of  Coventry, West Midlands, was just days into the three-week break with her husband Matt, 43, in September 2015 when she became fatigued and under the weather.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
This Guest Editorial introduces this month's special Pancreatic Cancer Theme Issue, a series of reviews intended to highlight the pathologic to molecular profiles and diagnoses of benign and neoplastic pancreatic lesions.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Guest editorial Source Type: research
Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease that is mostly diagnosed late in the course of the illness. Unlike other cancers in which measurable successes have been achieved with traditional chemotherapy, targeted therapy, and, recently, immunotherapy, PDAC has proved to be poorly responsive to these treatments, with only marginal to modest incremental benefits using conventional cytotoxic therapy. There is, therefore, a great unmet need to develop better therapies based on improved understanding of biology and identification of predictive and prognostic biomarkers that would guide therapy.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Review Source Type: research
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of only 8% and is estimated to be the second leading cause of cancer-related deaths by 2021. Prior convention held that screening for PDAC would not be beneficial; however, a deeper understanding of the carcinogenesis pathway supports a potential window of opportunity among the target population. Screening for PDAC is not a standard practice among the general population because of its low incidence. However, screening may be beneficial for individuals with familial history, chronic diseases with genetic predispositions, or inherited cancer syndromes, such a...
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Review Source Type: research
Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve the efficacy and likely outcomes of screening. In addition, the pathologic mechanisms that lead to the development of PDAC are discussed in an effort to further understand the targets of pancreatic cancer screening.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Review Source Type: research
Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is projected to become the second leading cause of cancer death in the United States. Despite significant advances in understanding the disease, there has been minimal increase in PDAC patient survival. PDAC tumors are unique in the fact that there is significant desmoplasia. This generates a large stromal compartment composed of immune cells, inflammatory cells, growth factors, extracellular matrix, and fibroblasts, comprising the tumor microenvironment (TME), which may represent anywhere from 15% to 85% of the tumor.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Health